Condition: Radiomic · Radiomics · Breast Cancer Metastatic · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.
This description comes directly from the study's public registry record.
Claudio Vernieri, MD, PhD · +390223903066 · claudio.vernieri@istitutotumori.mi.it
Leonardo Provenzano, MD · +390223903066 · leonardo.provenzano@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Nazionale Tumori | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07030569